1330262-09-3
1330262-09-3
Chemical Structure
Xipamide-d6
- CAS No.: 1330262-09-3
- Formula:C15H9D6ClN2O4S
- Molecular Weight:360.85
IUPAC Name: N-(2,6-bis(methyl-d3)phenyl)-4-chloro-2-hydroxy-5-sulfamoylbenzamide
InChIKey: MTZBBNMLMNBNJL-WFGJKAKNSA-N
SMILES: C(NC1=C(C([2H])([2H])[2H])C=CC=C1C([2H])([2H])[2H])(=O)C2=CC(S(N)(=O)=O)=C(Cl)C=C2O
Biological Activity: Xipamide-d6 is the deuterium labeled Xipamide. Xipamide is a sulfonamide-based diuretic. Xipamide is an antihypertensive agent able to selectively inhibit the anion exchanger (AE)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Xipamide-d6 | Xipamide-d6 is the deuterium labeled Xipamide. Xipamide is a sulfonamide-based diuretic. Xipamide is an antihypertensive agent able to selectively inhibit the anion exchanger (AE). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Xipamide (Standard) | ≥98% | Xipamide (Standard) is the analytical standard of Xipamide. This product is intended for research and analytical applications. Xipamide is a sulfonamide-based diuretic. Xipamide is an antihypertensive agent able to selectively inhibit the anion exchanger (AE). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Xipamide | 99.74% | Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na+/Cl--potassium transporter inhibitor with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl-/NaCO3- anion exchanger, and increases calcium reabsorption while promoting potassium and magnesium excretion. Xipamide is mainly cleared via the renal pathway and causes a temporary decrease in glomerular filtration rate under specific conditions. Xipamide does not affect Ca2+ signaling induced by endothelin-1 and other factors, nor does it inhibit various ion cotransport or pump activities in red blood cells. Xipamide can be used in researches related to cardiovascular diseases, hypertension (especially with left ventricular hypertrophy), advanced renal failure, and liver cirrhosis with ascites. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Prichard BN, et al. Xipamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs. 1985 Oct;30(4):313-32. [Content Brief]
